Free Trial

Compass Therapeutics (CMPX) Stock Price, News & Analysis

Compass Therapeutics logo
$2.78 +0.16 (+5.92%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$2.78 0.00 (0.00%)
As of 07/3/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Compass Therapeutics Stock (NASDAQ:CMPX)

Key Stats

Today's Range
$2.61
$2.87
50-Day Range
$1.69
$2.78
52-Week Range
$0.82
$4.08
Volume
794,726 shs
Average Volume
971,729 shs
Market Capitalization
$383.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67
Consensus Rating
Buy

Company Overview

Compass Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

CMPX MarketRank™: 

Compass Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 345th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Compass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Compass Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Compass Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Compass Therapeutics is -6.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Compass Therapeutics is -6.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Compass Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Compass Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.40% of the float of Compass Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Compass Therapeutics has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Compass Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving.
  • Dividend Yield

    Compass Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Compass Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.40% of the float of Compass Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Compass Therapeutics has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Compass Therapeutics has recently decreased by 0.54%, indicating that investor sentiment is improving.
  • News Sentiment

    Compass Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Compass Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Compass Therapeutics insiders have sold 10,841.37% more of their company's stock than they have bought. Specifically, they have bought $51,900.00 in company stock and sold $5,678,571.00 in company stock.

  • Percentage Held by Insiders

    29.80% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Compass Therapeutics' insider trading history.
Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMPX Stock News Headlines

CMPX Compass Therapeutics, Inc. - Seeking Alpha
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

CMPX Stock Analysis - Frequently Asked Questions

Compass Therapeutics' stock was trading at $1.45 at the beginning of 2025. Since then, CMPX stock has increased by 91.4% and is now trading at $2.7750.

Compass Therapeutics, Inc. (NASDAQ:CMPX) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12).

Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager.

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
7/05/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CMPX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$32.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+356.5%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$49.38 million
Pretax Margin
-6,496.59%

Debt

Sales & Book Value

Annual Sales
$850 thousand
Price / Cash Flow
N/A
Book Value
$0.91 per share
Price / Book
3.05

Miscellaneous

Free Float
97,075,000
Market Cap
$383.73 million
Optionable
Not Optionable
Beta
1.48
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CMPX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners